What is General Proximity?
General Proximity operates at the intersection of advanced biology and computational discovery. The company has engineered the first generalized, mechanism-agnostic proximity discovery engine, a platform designed to decode the complex language of molecular machines. At the core of its technology are effector proteins—including chaperones, adaptor proteins, and trafficking proteins—which serve as the primary regulators of biological processes. By mapping these post-translational modification (PTM) readers, writers, and erasers, General Proximity provides researchers with unprecedented insights into cellular mechanics. This capability positions the company as a critical infrastructure provider for the next generation of therapeutic development and synthetic biology, offering a scalable solution for identifying and manipulating intricate protein interactions within living systems.
How much funding has General Proximity raised?
General Proximity has raised a total of $16M across 1 funding round:
Angel/Seed
$16M
Angel/Seed (2025): $16M with participation from Felicis Ventures, Y Combinator, and The Rock Creek Group
Key Investors in General Proximity
Felicis Ventures
A Menlo Park-based venture capital firm that raises multistage funds to invest in early and growth-stage technology companies across sectors such as SaaS, AI, and fintech.
Y Combinator
A premier startup accelerator and seed funding provider based in Mountain View, known for supporting high-growth technology ventures from their inception.
The Rock Creek Group
A global investment firm focused on integrating innovation into investment strategies, with a strong emphasis on sustainability and multi-asset class growth.
What's next for General Proximity?
Looking ahead, General Proximity is poised to leverage its recent capital infusion to expand its technical infrastructure and deepen its research capabilities. The strategic roadmap involves refining its proximity discovery engine to handle higher throughput data, thereby increasing the precision of its effector protein mapping. As the company moves into this next phase of growth, it will likely focus on establishing key partnerships with pharmaceutical and biotechnology firms that require high-fidelity molecular insights. By maintaining its focus on mechanism-agnostic discovery, General Proximity is well-positioned to become a cornerstone of modern biological research, potentially setting new standards for how complex protein networks are analyzed and utilized in drug discovery and beyond.
See full General Proximity company page
